

## **Lupin Receives FDA Approval for Generic Loestrin® 24 Fe Tablets**

**Mumbai, Baltimore, November 3, 2015:** Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Blisovi 24 Fe Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) from the United States Food and Drug Administration (FDA) to market a generic version of Warner Chilcott's Loestrin® 24 Fe Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg). Lupin's US subsidiary, Lupin Pharmaceuticals Inc. would commence promoting the product shortly in the US.

Lupin's Blisovi 24 Fe Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) are the AB rated generic equivalent of Warner Chilcott's Loestrin® 24 Fe Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg). It is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Loestrin® 24 Fe had US sales of USD 56.8 million (IMS MAT June 2015).

### **About Lupin Limited**

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 6<sup>th</sup> largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions, IMS Health) and the 3<sup>rd</sup> largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8<sup>th</sup>) and South Africa (ranked 4<sup>th</sup> – IMS Health).

For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively. Please visit <http://www.lupin.com> for more information.

### **About Lupin Pharmaceuticals Inc.**

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, please do visit <http://www.lupinpharmaceuticals.com>

You could also follow us on Twitter – [www.twitter.com/lupinlimited](http://www.twitter.com/lupinlimited)

**CIN:** L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.

**For further information or queries please contact -**

## Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Shamsher Gorawara  
Head – Corporate Communications  
Ph: +91-98 20 338 555  
Email: [shamshergorawara@lupin.com](mailto:shamshergorawara@lupin.com)

or

Alpesh Dalal  
Head – M & A and Investor Relations  
Lupin Limited  
Ph: +91 98 20 023 511  
Email: [alpeshdalal@lupin.com](mailto:alpeshdalal@lupin.com)

*[\\*Safe Harbor Statement](#)*

*Loestrin® 24 Fe is the registered trademark of Warner Chilcott.*